OncLive TV

Soo Park, MD, discusses the role of cemiplimab-rwlc (Libtayo) in advanced basal cell carcinoma.

Harry H. Yoon, MD, discusses updated findings from the phase 3 RATIONALE-306 trial in esophageal squamous cell carcinoma.

Arndt Vogel, MD, discusses the outcomes of the phase 3 HIMALAYA trial in unresectable hepatocellular carcinoma.

Jason Luke, MD, FACP, discusses the importance of a multidisciplinary approach in basal cell carcinoma.

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of molecular testing in ovarian cancer.

Lee S. Schwartzberg, MD, FACP, discusses the utilization of genomics in cancer care.

Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.

Edward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.

Zeynep Eroglu, MD, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.

Gregory Botta, MD, PhD, discusses unmet needs in the salvage setting of gastrointestinal cancers.

Shilpa Gupta, MD, discusses the results of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

Matthew A. Lunning, DO, FACP, discusses how the FDA approval of lisocabtagene maraleucel expands treatment options for patients with large B-cell lymphoma.

Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.

John Nakayama, MD, discusses the current treatment landscape of ovarian cancer and where he hopes the field advances in the future.

Alok Khorana, MD, discusses increasing rates of young-onset pancreatobiliary adenocarcinoma.

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.

Suneel Kamath, MD, discusses the importance of including underrepresented patient populations in clinical trials.

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in patients with metastatic or unresectable melanoma, according to data from the phase 2/3 RELATIVITY-047 trial.

Hetty Carraway, MD, discusses the role of biomarker testing in patients with myelodysplastic syndromes and acute myeloid leukemia.

Alexander I. Spira, MD, PhD, FACP, discusses the activity of adagrasib in patients with non–small cell lung cancer and central nervous system metastases.

Bradley J. Monk, MD, FACS, FACOG, discusses the role platinum-based chemotherapy in recurrent ovarian cancer, plus emerging antibody-drug conjugates in the space.

Daniel J. DeAngelo, MD, PhD, discusses rates of cytokine release syndrome with obecabtagene autoleucel in acute lymphoblastic leukemia.

Amrita Krishnan, MD, discusses the effectiveness of teclistamab in relapsed/refractory multiple myeloma.

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.

Shahneen Sandhu, MD, discusses the design of the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Shilpa Gupta, MD, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.

Robert Wenham, MD, MS, FACOG, FACS, discusses the role of antibody-drug conjugates in ovarian cancer.

Ursula A. Matulonis, MD, discusses the current treatment landscape of recurrent ovarian cancer.

Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.